

**Supplementary Table e-2.** Clinical activity at one year of treatment according to MRI missing data at one year. **A)** in the whole cohort of patients, **B)** in fingolimod-treated patients and **C)** in natalizumab-treated patients.

<b>A) whole cohort of patients</b>	<b>Without missing MRI data at 1year (n=351)</b>	<b>With missing MRI data at 1year (n=278)</b>	<b>p value</b>
Patients with at least one year of treatment-n (%)	287 (81.8)	252 (90.7)	0.0019
Patients with relapse within the first year of treatment-n (%)			
≥1 relapse	108 (30.8)	43 (15.5)	<0.0001
≥2 relapses	26(7.4)	5 (1.8)	0.0013
EDSS score after one year of treatment-mean(SD)	2.5(1.4)	2.3(1.4)	0.0838
Patients with increase EDSS after one year-n (%)	97 (29.0)	36 (18.4)	0.0069

  

<b>B)fingolimod-treated patients</b>	<b>Without missing MRI data at 1year (n=143)</b>	<b>With missing MRI data at 1year (n=160)</b>	<b>p value</b>
Patients with at least one year of treatment-n (%)	111(77.6)	143 (89.4)	0.0075
Patients with relapse within the first year of treatment-n (%)			
≥1 relapse	52(36.4)	30 (18.8)	0.0007
≥2 relapses	13(9.1)	3 (1.9)	0.0081
EDSS score after one year of treatment-mean(SD)	2.3 (1.4)	2.1(1.4)	0.3973
Patients with increase EDSS after one year -n (%)	47(34.8)	18 (14.6)	0.0002

  

<b>C)natalizumab-treated patients</b>	<b>Without missing MRI data at 1year (n=208)</b>	<b>With missing MRI data at 1year (n=118)</b>	<b>p value</b>
Patients with at least one year of treatment-n (%)	176 (84.6)	109 (92.4)	0.0549
Patients with relapse within the first year of treatment- n (%)			
≥1 relapse (%)	56 (26.9)	13(11.0)	0.0007
≥2 relapses (%)	13(6.3)	2(1.7)	0.0954
EDSS score after one year of treatment-mean(SD)	2.6 (1.4)	2.5 (1.4)	0.5172
Patients with increase EDSS after one year- n (%)	50 (25.1)	18 (24.7)	1.0000